SG Americas Securities LLC Takes Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

SG Americas Securities LLC purchased a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 63,984 shares of the company’s stock, valued at approximately $129,000.

A number of other institutional investors have also recently added to or reduced their stakes in TSHA. Avoro Capital Advisors LLC grew its stake in shares of Taysha Gene Therapies by 328.2% during the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares in the last quarter. StemPoint Capital LP purchased a new position in Taysha Gene Therapies in the first quarter valued at about $3,122,000. Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies during the 2nd quarter valued at approximately $1,018,000. Rhumbline Advisers purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $413,000. Finally, Privium Fund Management B.V. purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $213,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $1.99 on Friday. The stock has a market capitalization of $372.17 million, a PE ratio of -4.06 and a beta of 0.40. The business’s fifty day moving average price is $2.11 and its 200 day moving average price is $2.48. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. Taysha Gene Therapies, Inc. has a 12-month low of $1.27 and a 12-month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. During the same period last year, the firm posted ($0.38) EPS. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on TSHA. Canaccord Genuity Group reduced their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Needham & Company LLC decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Piper Sandler cut their target price on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a research note on Monday, July 1st. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $6.38.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.